CNS Tumor (IDH1 Mutation): Molecular Oncology Tumor Boards

This free case-based activity includes a crowd-sourced discussion of a 41-year-old woman who developed new onset right focal seizures and aphasia in 2004. MRI revealed a non-enhancing left parietal mass that was followed after seizures were controlled with an anti-epileptic. In 2013, she developed increased seizure frequency and MRI showed slow progression of the non-enhancing left parietal mass and now a faint hint of enhancement could be seen.

Originally posted on a forum in the ASCO Connection, participants now have the opportunity to claim CME, completion, or participation certificates for completing this activity.

Learning Objectives

  • Demonstrate the clinical management decisions for a patient with a grade II oligodendroglioma that initially presented with seizures
  • Convey the importance of using IDH testing in the diagnosis and clinical management of patients with diffuse gliomas
  • Explain the classification of oligodendroglioma, which now incorporates IDH mutation and 1/19q co-deletion into the definition

Continuing Education Credit

1 Credit/Point is available for participation in this course. Certificate and credit types available include:

  • AMA PRA Category 1 Credits™ 
  • ABIM MOC Points
  • Certificate of Participation may be used to confer credit; however, all final decisions regarding the awarding of credits will be made by the licensing organization to which the credits are submitted.
  • Certificate of Completion may be used to document participation, but no credit will be conferred.
Important Notes
  • This course expires on June 29, 2019. Participants must complete all necessary course components by this date to receive credit.